Drug companies are eyeing a popular opioid bill to roll back discounts for Medicare beneficiaries, but opposition has quickly mobilized.
Drug companies are eyeing a popular opioid bill to roll back discounts for Medicare beneficiaries, but opposition has quickly mobilized.